Navigation Links
Out-of-whack protein may boost Parkinson's
Date:2/26/2008

GAINESVILLE, Fla. A single change in a protein may play a role in whether someone develops Parkinsons disease, say University of Florida Genetics Institute researchers writing in a recent issue of the Proceedings of the National Academy of Sciences.

Scientists studying rats induced to display a form of Parkinsons disease discovered that a protein commonly found in brain cells can be toxic if at one pinpoint location in its amino acid structure it lacks a chemical compound called a phosphate.

When scientists used gene therapy to simulate a phosphate at this critical position, the rats brain cells didnt develop the Parkinson-like pathology that would normally occur.

The finding provides new insight into the fundamentals of Parkinsons disease and the role of an abundant yet mysterious brain protein known as alpha-synuclein, which is believed to help brain cells communicate but may have a more sinister role in the development of neurological diseases.

We have another potential target for therapy, but there is a great deal left to discover, said Nicholas Muzyczka, Ph.D., a professor of molecular genetics and microbiology in the College of Medicine and an eminent scholar with the UF Genetics Institute. This is one more piece of information about what might be causing the toxicity in Parkinsons disease, and it gives us a little more to go on about what alpha-synuclein does in the brain.

Generally located at the synapses of nerve cells, alpha-synuclein is believed to aid in brain function, possibly by helping cells communicate with one another by controlling the release of neurotransmitters such as dopamine.

Mutations of alpha-synuclein may cause a rare, inherited form of Parkinsons, and the protein has been found to be the major component of Lewy bodies, which are abnormal clusters of protein in the brain cells of patients with Parkinsons disease.

The National Parkinson Foundation estimates 1.5 million Americans currently have Parkinsons disease and about 60,000 new cases are diagnosed each year. It is caused by the death or impairment of certain nerve cells in a part of the brain called the substantia nigra. When these cells die, the body is deprived of dopamine, a neurotransmitter vital for movement.

We know of several enzymes that can cause phosphorylation in the proper position of the alpha-synuclein protein, said Oleg Gorbatyuk, Ph.D., an assistant professor of molecular genetics and microbiology. Increasing their expression in brains afflicted with Parkinsons disease could possibly provide a gene therapy approach to the disease.

In experiments described in the Jan. 15 issue of PNAS, UF researchers used gene transfer to enhance the production of three versions of alpha-synuclein in the substantia nigra region on one side of the rats brains. The other side was not treated, for comparison purposes.

Of the types of alpha-synuclein, the one that simulated phosphorylation at position 129 of the protein was nontoxic. But the other versions of the protein all caused significant loss of dopamine neurons in the substantia nigra.

Adding a phosphate group is about the smallest thing that can possibly happen in biology, said Mark R. Cookson, an investigator in the Cell Biology and Gene Expression Unit of the National Institute on Aging who was not involved in the research. But this relatively minor, innocuous change can switch everything around from being a big problem to being no problem. This research really gives us an idea of some things going on in inherited cases of Parkinsons disease, and if we use that genetic information as a handle to get into the common disease, it is possible to take this from genetics to a drug discovery program.


'/>"/>

Contact: John D. Pastor
jdpastor@ufl.edu
352-273-5815
University of Florida
Source:Eurekalert

Related medicine news :

1. Scientists identify proteins that help bacteria put up a fight
2. Protein shines light on cancer response
3. 3 newly discovered ERK pathway proteins related to CagA induced disease
4. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
5. Oncoproteins double-team and destroy vital tumor-suppressor
6. Lack of Brain Protein May Explain Rain Man Abilities
7. Discovery of overdrive protein could broaden drug design options
8. Burn Fat with fucoPROTEIN(TM) Bars
9. Unsuspected protein determines resistance to breast cancer treatment
10. Breaking down Huntingtons disease one protein at a time
11. New findings show Enbrel significantly reduced levels of C-reactive protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing ... Up Springboard, an automotive invention that improves the storage features of a pick ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
(Date:4/26/2016)... April 26, 2016 US demand for ... expand 4.9 percent annually to $27.6 billion in ... facilities to decrease rates of healthcare-associated infections (HAIs) ... equipment, and services.  Although declining, the overall rate ... targeted levels set by the CDC.  Recent statistics ...
Breaking Medicine Technology: